

" " " "

" " " "

1		
2		
3		
4		2023
5		2023
6		

7		
8		2020 1
9		
10		
11		2023 2024 1 24 " "
12		2023

13		2023
14		2023
15		
16	15	2023

2024 1 24

" "

2024

5

"

"

"

IPO

5,449.90

503.58

2023 3

5,449.90

2,040.38

1,536.8

936.62

182

154

2

---

2012 44

2 ---

2022 15

"

1

2

3

936.62

2024

2023

2024 2 1

2

---

1 --

1

2

3

1

2

3

4.0



2023

2023

	<b>2023-12-31/ 2023</b>	<b>2022-12-31/ 2022</b>	<b>(%)</b>	<b>2021-12-31/ 2021</b>
	94,387.09	114,095.05	-17.27	87,505.30
	19,370.87	32,486.48	-40.37	30,286.47
	16,251.86	29,768.84	-45.41	26,151.26
	20,158.64	4,493.82	348.59	17,300.86
	287,804.71	277,891.45	3.57	251,486.68
	304,714.03	295,924.27	2.97	270,152.18

2023

	<b>2023</b>	<b>2022</b>	<b>(%)</b>	<b>2021</b>
	1.5858	2.6614	-40.41	2.4812
	1.5858	2.6614	-40.41	2.4812
	1.3305	2.4388	-45.44	2.1424
%	6.89	13.03	6.14	12.64
%	5.78	11.94	6.16	10.92



%	21.43	16.74	4.69	15.67
---	-------	-------	------	-------

1	943,870,865.67	17.27%
2		40.37%
		45.41%
3		348.59%
17,932.87	25.50%	
4		40.41%
6.14		

		1	
2	3		4
	5	6	
2023			

2023

**1**

2023

20,224.50

5.88%

21.43%


1 **003**  
3,706

4,937 3,706  
500 3,706  
2 2023 10 27  
2023 10 31 2023  
6 è



(本页无正文，为《国信证券股份有限公司关于广东奥普霖中药股份有限公司  
2023年度持续督导跟踪报告》之签章页)

保荐代表人签字：



李钦军



唐永兵



2024年 4月 29日